Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 16;3(5):466–473. doi: 10.1016/j.hroo.2022.05.012

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Heart Rhythm Society. Published by Elsevier Inc.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Risk of hematoma stratified by anticoagulant (AC) and antiplatelet (AP) use. Bar chart depicting hematoma rates within 30 days of the patients’ index procedures stratified by antithrombotic use. Hazard ratios (HR), 95% confidence interval (CI), and P values are calculated using Cox proportional regression modeling. Hematoma rates varied substantially based on AC use, type (warfarin or direct oral anticoagulant [DOAC]), and with or without use of AP, which was associated with an almost doubling of hematoma risk vs no AP use (HR: 1.85, P = .0006) in the general cohort. Among the type of AC used, the risk of hematoma was higher in the warfarin group vs DOAC (HR: 1.71; 95% CI 1.00–2.90; P = .0487).